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with n-HFL patients comparing the use of filgrastim after
peripheral blood progenitor cells reinfusion.
METHODS: Multi-centre study conducted in France be-
tween 1995-1999 including 51 patients (24 placebo (P)
and 27 filgrastim (FI)). Demographic, disease and treat-
ment-specific information was collected through the
CRF. QoL assessment per patient over 90 days of follow-
up (FU) was calculated as follows. QoL-index valued
from 0 (worst) to 1 (best) was used to assign QoL per
hospital day: in sterile room (SR)  0.6; in a normal
room (NR)  0.9. Each adverse event (AE) (WHO grade
3 or 4) affected the QoL index with an additional factor
of 0.8, 0.6, 0.4 or 0.2 respectively for 1, 2, 3, 	 4 con-
comitant AEs per patient per day. Average QoL-scores
over time per treatment arm were compared using Kaplan-
Meier statistics (p  .05, two-sided). Sensitivity analysis
on the score index over the FU was undertaken.
RESULTS: For FI the average days with 0, 1, 2, 3, 4
AEs in a SR was 6.59, 4, 2.56, 0.81, 0.37 and in a NR,
1.59, 1.67, 0.56, 0.11, 0. For P in a SR we had respec-
tively 8.3, 3.8, 2.8, 2.2, 0.125 and in a NR, 2.13, 0.9, 0,
0, 0. Average estimated QoL-score was 81.71 for FI (SD:
3.15, range: 72.54–85.24) and 80.66 for C (SD: 3.01,
range: 71.8–84.68) (Mann Witney U test: p  0.49 but
decreased to 0.25 for first hospitalization period). Kap-
lan-Meier graph demonstrates after day 16 a constant
QoL benefit for FI due to earlier hospital discharge (Log
rank test: 27.2; p  .001).
CONCLUSION: Filgrastim use 24 hours post-PBPC in
high dose treatment of n-HFL patients is associated with
QoL improvement due to earlier hospital discharge.
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OBJECTIVE: It is assumed that genetic testing for breast-
ovarian cancer predisposition in the context of peer-re-
viewed research protocols at academic centers offers pro-
tection against test-related distress. However, BRCA1/2
genetic testing under research protocols often implies a
significant time delay before the test result can be dis-
closed, which would not apply to commercially available
testing. Using data from our own research setting, we in-
vestigated whether delay in getting BRCA1/2 test results
was associated with participants’ distress.
METHODS: Participants were 128 women from 26
French Canadian kindred with a BRCA1/2 germline mu-
tation identified. Genetic counseling was provided in a
pre-test education session and a result disclosure session.
Of the women tested, 53 (41%) were found to be carriers
of the familial mutation and 75 (59%), non-carriers.
Mean age at enrollment (48.4 yrs 
 12.1) was similar for
the two groups. Test-related distress was assessed by the
Impact of Event Scale one month after result disclosure.
RESULTS: Time interval between blood sample for test-
ing and result disclosure varied considerably (range: 35
to 756 days), and was similar for carriers (mean  172 

120 days) and non-carriers (mean  174 
 174 days).
Among non-carriers, those given their result less than six
months following blood draw (n  48) tended to have
lower levels of test-related distress (mean  3.3 
 5.2)
than those who were told their result beyond 6 months (n 
27, mean  7.8 
 11.2, p  0.06). For carriers, test-
related distress did not differ according to whether they
were given their result less than six months (n  35,
mean  10.4 
 13.7) after the blood draw or later (n 
18, mean  9.8 
 12.2).
CONCLUSIONS: Consistent with others, these results
indicate that most women cope well with test informa-
tion in research settings with careful expert counseling.
Nevertheless, our findings among non-carriers suggest
that prompt disclosure of BRCA1/2 test results has po-
tential quality-of-life benefits.
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OBJECTIVE: The EORTC QLQ-C30 is one of the most
widely used QL measures in cancer clinical trials. This
study aimed to look at the psychometric properties of the
QLQ-C30 in 32 countries with a database of 9000 pa-
tients.
METHOD: All EORTC studies incorporating the EORTC
QLQ-30 were systematically selected for this study. In-
clusion criteria for trials were if the trial containing the
QLQ-C30 responses had been coded into the EORTC
database. One hundred fourteen EORTC studies were re-
viewed of which 52 met the criteria for being included in
the final analysis.
RESULTS: The majority of cancer patients were receiv-
ing palliative care for primary cancers including mela-
noma, prostate, head and neck, breast and lung cancers
and 90% of the patients were distributed over 10 out of
the 32 countries. At least one item of data was missing in
14 to 17% of patient questionnaires completed, though
the average percentage of missing items per patient
ranged from 1.1% to 1.5% Particular items relating to
Role Functioning and Financial Difficulties were the most
common items missing (3%). Factor analyses for all three
versions of the questionnaire are similar, though some
